Innate Pharma SA Total Current Liabilities 2012-2023 | IPHYF

Innate Pharma SA total current liabilities from 2012 to 2023. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.

Innate Pharma SA Total Current Liabilities 2012-2023 | IPHYF

Innate Pharma SA total current liabilities from 2012 to 2023. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.5B
Takeda Pharmaceutical (TAK)$43.4B
Merck (MKKGY)$21B
Astellas Pharma (ALPMY)$20.3B
Sandoz Group AG (SDZNY)$19.9B
United Therapeutics (UTHR)$17.9B
Summit Therapeutics (SMMT)$16.1B
Neurocrine Biosciences (NBIX)$12.9B
Shionogi (SGIOY)$12.3B
Catalent (CTLT)$10.8B
Jazz Pharmaceuticals (JAZZ)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.4B
Orion OYJ (ORINY)$6.8B
Corcept Therapeutics (CORT)$6.2B
Ionis Pharmaceuticals (IONS)$6.1B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.8B
Dyne Therapeutics (DYN)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.8B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.6B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2.2B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.8B
Evotec AG (EVO)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.7B
ARS Pharmaceuticals (SPRY)$1.7B